Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-15-003820
Filing Date
2015-05-11
Accepted
2015-05-11 07:00:41
Documents
12
Period of Report
2015-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20150331.htm 10-Q 1408059
2 EX-31.1 akba-ex31_2015033111.htm EX-31 15201
3 EX-31.2 akba-ex31_201503319.htm EX-31 15260
4 EX-32.1 akba-ex32_201503317.htm EX-32 12846
5 EX-99.1 akba-ex99_2015033110.htm EX-99 87834
6 GRAPHIC g201505081941548842297.jpg GRAPHIC 1997
  Complete submission text file 0001564590-15-003820.txt   8364501

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT akba-20150331.xml EX-101.INS 1443800
8 XBRL TAXONOMY EXTENSION SCHEMA akba-20150331.xsd EX-101.SCH 36377
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20150331_cal.xml EX-101.CAL 43743
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20150331_def.xml EX-101.DEF 111616
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20150331_lab.xml EX-101.LAB 287237
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20150331_pre.xml EX-101.PRE 233951
Mailing Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1100 CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 15848838
SIC: 2834 Pharmaceutical Preparations